1. Home
  2. Research
  3. Research Groups
  4. Molecular Pathology of Cancer Group

Molecular Pathology of Cancer Group

Search for publications

Only original articles, editorials, guidelines.

  • Smith M, Piulats J, Todenhöfer T, Lee JL, Arija JA, Mazilu L, Azad A, Alonso-Gordoa T, McGovern U, Choudhury A, Horvath L, Ye D, Han W, Suzuki H, Uemura H, McKay R, Ades S, Fléchon A, Pieczonka C, Fernandes MS, Hulstijn M, Lithio A, Nacerddine K, Agarwal N.

    Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

    LANCET ONCOLOGY . 26(11): 1489-1500. Number of citations: 3

    [doi:10.1016/S1470-2045(25)00475-9]

  • Lopez-Janeiro A, Brizzi E, Ruz-Caracuel I, Alexandru R, de Andrea C, Berjón A, Yebenes L, Mendiola M, Heredia-Soto V, Montero-Calle A, Barderas R, de Los Rios V, Redondo A, Pelaez-Garcia A, Hardisson D.

    The Proteomic Landscape of CTNNB1 Mutated Low-Grade Early-Stage Endometrial Carcinomas

    Cells . 14(21): . Number of citations: 1

    [doi:10.3390/cells14211676]

  • Martínez-Puente N, Ruz-Caracuel I, Leandro-García LJ, Pian-Arias H, Vega-Corral Z, Letón R, Radu R, Berrizbeitia M, Mellid S, Reglero C, Salazar-Hidalgo ME, Arroba E, Díaz-Talavera A, Marazuela M, Benito-Berlinches A, González-García I, Campos-Mena S, Lozano-Escario MD, Guadalix S, Calatayud M, Pérez-Campos A, Lahera M, Cascón A, Galofré JC, Currás-Freixes M, Caleiras EJ, Valderrabano P, Robledo M, Montero-Conde C.

    Expression of Homo Sapiens (Hsa)-miR-139-5p as a Clinically Feasible Prognostic Marker for Differentiated Thyroid Cancer

    LABORATORY INVESTIGATION . 105(10): 104199-104199.

    [doi:10.1016/j.labinv.2025.104199]

  • Servitja S, Castro-Henriques M, Álvarez-Busto I, Díez-Franco C, Medina-Castillo A, Algarra-García MA, López-Miranda E, Lario-Martínez M, Luengo-Alcázar MI, Borregón M, Davó A, Gasull-Delgado A, Roque-García S, Gonzaga-López A, Poveda-Ferriols JM, Pascal S, Mitroi-Marinescu AM, García-Escolano M, Fernández-Carvajal A, Ferrándiz-Huertas C, Ferrer-Montiel A.

    A topical nociceutical formulation ameliorates chemotherapy-induced peripheral neuropathy: a pilot randomized clinical study

    Clinical & Translational Oncology . 28(3): 1040-1048. Number of citations: 1

    [doi:10.1007/s12094-025-04062-1]

  • Soria A, Díaz A, Iruzubieta P, Martín-Mateos R, Salcedo-Allende MT, Jiménez-Masip A, Fuster-Anglada C, Arias-Loste MT, Perna C, El Maimouni C, Pericas JM, Ferrer-Gómez A, González CJ, Muñoz-Martínez S, Padilla M, Crespo J, Calixto Z, Sabiote C, Albillos A, Cervera M, Olivas I, Arvaniti P, Hernández-Évole H, Jiménez-Esquivel N, Gratacós-Ginès J, Juanola A, Pose E, Coll M, Nadal R, Pérez-Guasch M, Fabrellas N, Ginès P, Londoño MC, Graupera I.

    Autoantibodies are associated with worse outcomes in MASLD

    JHEP REPORTS . 7(10): 101470-101470. Number of citations: 1

    [doi:10.1016/j.jhepr.2025.101470]

  • Konstantinopoulos PA, Kim JW, Freyer G, Lee JY, Gaba L, Grisham RN, Colombo N, Wu X, Sehouli J, Cruz F, Cibula D, Monk BJ, Nyvang GB, Friedlander M, Lorusso D, Van Nieuwenhuysen E, Malik R, Glasspool R, Marth C, Leary A, Cortés-Salgado A, Zamagni C, Marmé F, Sufliarsky J, Hinson P, Zuradelli M, Wang C, Su F, Paule I, Miller M, Matulonis UA, González-Martín A.

    Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation

    JOURNAL OF CLINICAL ONCOLOGY . 43(26): 2908-2917. Number of citations: 3

    [doi:10.1200/JCO-25-00225]

  • Eskander RN, Corr B, Cibula D, Tan DSP, Cloven N, Guerra E, Hasegawa K, Myers T, You B, Makker V, Zagouri F, Gien LT, Bartoletti M, Mallen A, Woelber L, Mocci S, Komatsubara K, Ma L, Colombo N.

    A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society . : 102654-102654.

    [doi:10.1016/j.ijgc.2025.102654]

  • Aguzzi C, De Summa S, Molina-Cerrillo J, Alonso-Gordoa T, Nabissi M, Rizzo M, Zeppellini A, Sunela K, Sorgentoni G, Ortega C, Massari F, Marques Monteiro FS, Battelli N, Porta C, Santoni G, Santoni M.

    mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1a)

    Biochemistry and Biophysics Reports . 43: 102162-102162.

    [doi:10.1016/j.bbrep.2025.102162]

  • Quindós-Varela M, Soto de Prado-Otero D, Gallego A, García Y, Guerra E, Estévez-García P, Barretina-Ginesta MP, Borraz P, González-Martín A, Rubio MJ.

    Management and Clinical Outcomes of Patients with Advanced Ovarian Cancer in Routine Clinical Practice in Spain: The OVOC Study

    Oncology and therapy . 13(3): 631-648.

    [doi:10.1007/s40487-025-00347-1]

  • Massari F, Mollica V, Kopp RM, Grande E, Fiala O, Kanesvaran R, Li H, Schieber TJ, Juan Fita MJ, Poprach A, Lolli C, Bourlon MT, de Liaño AG, Grillone F, Sunela K, Rizzo A, Ghosn M, Cerbone L, Taha T, Ürün Y, Molina-Cerrillo J, Alonso-Gordoa T, Lenci E, Martin IO, Abu-Sini H, Rescigno P, Bhuva D, Fay AP, Conteduca V, Yildirim A, Rosellini M, Akova U, Tassinari E, Bölek H, Soares A, Marques Monteiro FS, Buti S, Bilen MA, Santoni M.

    Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study

    European Urology Focus . 11(5): 736-746. Number of citations: 2

    [doi:10.1016/j.euf.2025.05.020]

  • Manso L, Sánchez-Bayona R, Guerra JA, Cortés-Salgado A, Cejalvo JM, Garcia-Saenz JA, Morales S, González-Cortijo L, Mourón S, Bueno MJ, Garma LD, Quintela-Fandino M.

    A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer

    Cancer Research Communications . 5(9): 1728-1737.

    [doi:10.1158/2767-9764.CRC-25-0428]

  • López-Miranda E, Pérez-García JM, Gión M, Ribelles N, Cortez-Castedo P, Alonso-Romero JL, García MM, González-Santiago S, Bermejo B, Morales S, Carañana V, Garrigós L, Fernández-Pinto M, García-Vicente S, Garcia-Sanz A, Mena-Molina A, Boix O, Alcalá-López D, Llombart-Cussac A, Cortés J.

    Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial

    BREAST CANCER RESEARCH . 27(1): 141-141. Number of citations: 1

    [doi:10.1186/s13058-025-02089-4]

  • Kime A, Bataillon G, Treilleux I, Callens C, Selle F, Heitz F, Cinieri S, González-Martin A, Schauer C, Lindahl G, Parma G, Vergote I, Matsumoto T, Blonz C, Canzler U, Mosconi AM, Guerra Alía EM, Pujade-Lauraine E, Genestie C, Ray-Coquard I, Just PA.

    Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma? Lessons From the PAOLA-1/ENGOT-ov25 Trial, a GINECO Study

    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE . 149(8): 741-750. Number of citations: 2

    [doi:10.5858/arpa.2024-0081-OA]

  • Gion M, Blancas I, Cortez-Castedo P, Cortés-Salgado A, Marmé F, Blanch S, Morales S, Díaz N, Calvo-Plaza I, Recalde S, Martínez-Bueno A, Ruiz-Borrego M, Llabrés E, Taberner MT, de Laurentiis M, García-Vicente S, Guerrero JA, Boix O, Rodríguez-Morató J, Sampayo-Cordero M, Antonarelli G, Pérez-García JM, Cortés J, Llombart-Cussac A.

    Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial

    NATURE MEDICINE . 31(8): 2746-2754. Number of citations: 14

    [doi:10.1038/s41591-025-03734-3]

  • Zapatero A, Alonso-Gordoa T, Rodríguez Antolín A, Couñago F, Sanmamed N, Domínguez Esteban M, López Valcárcel M, Manneh R, Borque-Fernando Á, Sala González N, Maroto P.

    Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach.

    Oncology Reviews . 19: 1599292-1599292. Number of citations: 2

    [doi:10.3389/or.2025.1599292]

  • Bourlon MT, Galli L, Grande E, Park SH, Melichar B, Schieber TJ, Juan-Fita MJ, Ürün Y, Molina-Cerrillo J, Alonso-Gordoa T, De Giorgi U, Kucharz J, Pérez Calabuig E, Conteduca V, Taha T, Rescigno P, Abu-Sini H, Spinelli GP, Manneh Kopp R, Salfi A, Bhuva D, Valdez-Sandoval P, Mendez-Bribiesca S, Fiala O, Buti S, Marques Monteiro FS, Bamias A, Ghosn M, Massari F, Ansari J, Santoni M.

    Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study

    Frontiers in Oncology . 15: 1605282-1605282. Number of citations: 3

    [doi:10.3389/fonc.2025.1605282]

  • Manneh R, Molina-Cerrillo J, de Velasco G, Ibatá L, Martínez S, Ruiz-Granados Á, Alonso-Gordoa T.

    PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis

    PHARMACEUTICALS . 18(7): .

    [doi:10.3390/ph18071015]

  • Pérez-García JM, Gion M, Ruiz-Borrego M, Blancas I, López-Miranda E, Blanch S, Recalde S, Rendo CR, González X, Ancizar N, Morales S, Cortez P, Piwowarska Z, Shimizu E, Guerrero JA, Sampayo-Cordero M, Martínez-Bueno A, Cortés J, Llombart-Cussac A.

    Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial

    EClinicalMedicine . 85: 103309-103309. Number of citations: 7

    [doi:10.1016/j.eclinm.2025.103309]